Almirall Management

Management criteria checks 2/4

Almirall's CEO is Carlos Gallardo Piqué, appointed in Jan 2022, has a tenure of 2.33 years. directly owns 0% of the company’s shares, worth €7.79K. The average tenure of the management team and the board of directors is 2.8 years and 8.9 years respectively.

Key information

Carlos Gallardo Piqué

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.3yrs
CEO ownership	0.0004%
Management average tenure	2.8yrs
Board average tenure	8.9yrs

Recent management updates

Recent updates

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15

Almirall, S.A. (BME:ALM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 02

Would Shareholders Who Purchased Almirall's (BME:ALM) Stock Five Years Be Happy With The Share price Today?

Jan 20

Here's What Almirall, S.A.'s (BME:ALM) Shareholder Ownership Structure Looks Like

Jan 07

Should You Use Almirall's (BME:ALM) Statutory Earnings To Analyse It?

Dec 24

CEO

Carlos Gallardo Piqué (51 yo)

2.3yrs

Tenure

€50,000

Compensation

Mr. Carlos Gallardo Piqué serves as President at Almirall S. A. since January 2024. He has been Chairman of Board at Almirall, S.A. since May 06, 2022. He serves as Chief Executive Officer at Almirall, S.A...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Carlos Gallardo Piqué	CEO, President	2.3yrs	€50.00k	0.00043% € 7.8k
Michael McClellan	CFO & Member of Management Board	4.5yrs	no data	no data
Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	no data	no data	no data
Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	no data	no data	no data
Volker Koscielny	Chief Medical Officer & Member of Management Board	4.3yrs	no data	no data
Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	3.3yrs	no data	no data
Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	3.3yrs	no data	no data
Isabel Gomes	Company Vice Secretary	2.3yrs	no data	no data
Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	2.3yrs	no data	no data
Pablo del Fraile	Senior Director of Investor Relations	no data	no data	no data
Xavier Alba	Acting CSO and Head of R&D	no data	no data	no data
Daniel Ripley Soria	Company Secretary	2.3yrs	no data	no data

2.8yrs

Average Tenure

Experienced Management: ALM's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Carlos Gallardo Piqué	CEO, President	9.8yrs	€50.00k	0.00043% € 7.8k
Sidney Taurel	Member of Global Advisory Board-Spain	15.3yrs	no data	no data
Thomas Fulton McKillop	Independent First Vice Chairman	15yrs	€132.00k	no data
Enrique de Leyva Perez	Lead Independent Director	5.3yrs	no data	0.010% € 181.2k
Karin Louise Dorrepaal	External Independent Director	11.3yrs	€122.00k	no data
Eva-Lotta Coulter	Independent Director	3.7yrs	no data	no data
Ruud Dobber	Independent Director	2.9yrs	no data	no data
Antonio Gallardo Torrededia	Proprietary Director	9.8yrs	€50.00k	0.000090% € 1.6k
Seth Orlow	External Independent Director	8yrs	no data	no data
Alexandra Kimball	Independent Director	3.7yrs	no data	no data

8.9yrs

Average Tenure

64yo

Average Age

Experienced Board: ALM's board of directors are considered experienced (8.9 years average tenure).

Almirall Management

Management criteria checks 2/4

Key information

Recent management updates

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A., Annual General Meeting, May 05, 2023

Almirall, S.A. Announces Executive Changes

Almirall, S.A. Announces Executive Changes

Recent updates

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis

First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020)

Consensus forecasts updated

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

New 90-day high: €12.19

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Revenue behind estimates

Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019)

Analysts lower EPS estimates to €0.46